Wolfgang Miesbach: Protecting Liver Health in Bleeding Disorders
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a proud post on LinkedIn:
”World Hepatitis Day 2025 – Protecting Liver Health in Bleeding Disorders. Despite curative therapies for hepatitis B and C, people with congenital bleeding disorders (PWBD) remain at elevated risk for liver complications—including fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Landmark data show that even after viral eradication, factors such as metabolic dysfunction, obesity, diabetes, and alcohol drive ongoing liver injury.
New International Guidance (EAHAD, EHC, ISTH, WFH) by La Mura et al. provides a unified, evidence-based framework to proactively monitor, prevent, and manage liver complications in PWBD:
– Universal viral hepatitis screening for all PWBD exposed to blood derivatives, including assessment for occult HBV prior to immunosuppression/gene therapy
– Routine metabolic assessment (focus on MASLD and alcohol), as non-viral liver disease now rivals viral hepatitis in this population
– Non-invasive fibrosis stratification using FIB-4 and FibroScan, reducing need for biopsies and identifying patients at risk of progression
– HCC surveillance (liver ultrasound + AFP every 6 months) for those with advanced fibrosis or cirrhosis—even post-cure
– Gene therapy safety: Comprehensive liver evaluation is essential pre- and post-AAV gene therapy; advanced liver disease remains a contraindication”
Read the full article here.
Article: ”The management of liver disease in people with congenital bleeding disorders: guidance from European Association for Haemophilia and Allied Disorders, European Haemophilia Consortium, ISTH, and World Federation of Hemophilia”
Journal: JTH (Journal of Thrombosis and Haemostasis)
Authors: Vincenzo La Mura, Massimo Colombo, Graham R. Foster, Paolo Angeli, Wolfgang Miesbach, Robert Klamroth, Glenn F. Pierce, Brian O’Mahony, Ming Y. Lim, Virginia Hernandez-Gea, Michael Makris, Flora Peyvandi
Stay updated on the latest scientific advancements in the field of bleeding disorders with Hemostasis Today.
-
Apr 6, 2026, 16:39Dhinesh Selvaraju: FDA Approves Narsoplimab (Yartemlea) as 1st Treatment for TA-TMA in Adults and Children
-
Apr 6, 2026, 16:38Linda Vorberg: A Detailed Analysis on The Usefulness of CT for DL-Based Stroke Lesion Segmentation
-
Apr 6, 2026, 16:37Colleen Hearn: Telestroke Helps Resource-Limited Facilities Gain Access to Unavailable Expertise
-
Apr 6, 2026, 16:37Nicolas Hubacz: AI Maps Neuroplasticity in Stroke Recovery – How the Brain Adapts After Injury
-
Apr 6, 2026, 16:36Cristina de Diego Alonso: Movement Is Not Just an Exercise, It Is The Rhythm of Daily Life
-
Apr 6, 2026, 16:35Charles Okyere Boadu: What Is The Most Likely Cause of Persistent Thrombocytopenia Despite Transfusion?
-
Apr 6, 2026, 16:34Tumor Mutations and VTE Risk – New Insights from a 12,500-Patient Cancer Study – JTH
-
Apr 6, 2026, 16:31Wolfgang Miesbach: New Real-World Data Reveal Ongoing Burden in Moderate-to-Severe Haemophilia A
-
Apr 6, 2026, 16:26Heghine Khachatryan։ Targeting High Risk Antiphospholipid Syndrome in Pregnancy with Hydroxychloroquine